title: Fulminant hepatitis due to cyproterone acetate.
authors.forename: H
authors.initials: H
authors.lastname: Lévesque
authors.forename: C
authors.initials: C
authors.lastname: Trivalle
authors.forename: N D
authors.initials: ND
authors.lastname: Manchon
authors.forename: J P
authors.initials: JP
authors.lastname: Vinel
authors.forename: N
authors.initials: N
authors.lastname: Moore
authors.forename: J
authors.initials: J
authors.lastname: Hémet
authors.forename: H
authors.initials: H
authors.lastname: Courtois
authors.forename: E
authors.initials: E
authors.lastname: Bercoff
authors.forename: J
authors.initials: J
authors.lastname: Bourreille
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D003534:Cyproterone / Q000009:adverse effects / Q000031:analogs & derivatives*; D017373:Cyproterone Acetate; D005260:Female; D006501:Hepatic Encephalopathy / Q000139:chemically induced; D006801:Humans; D008297:Male
chemical_list: D000970:Antineoplastic Agents; D017373:Cyproterone Acetate; D003534:Cyproterone